Retacrit~R (epoetin zeta) is the first biosimilar epoetin to achieve a subcutaneous licence in renal anaemia

摘要

Retacrit licence expanded to include SC administration in renal anaemiaFurther to compelling evidence from a recent, large-scale, phase IE trial, the European Commission has granted approval for the SC administration of Retacrit in the treatment of anaemia associated with chronic renal disease [2]. Retacrit is the first biosimilar epoetin to be licensed in the European Union for both SC and intravenous (IV) administration in the nephrology setting. This new approval provides greater flexibility for prescribing physicians and their patients, and may confer considerable cost savings for healthcare organisations.